Rare diseases impact 1 in 10 Americans, and over 400 million people worldwide. The current development and FDA approval process can cost hundreds of millions of dollars – and take an average of 15 years – to develop one therapy. For the 30% of children diagnosed with a...

July 9, 2020

National Burden of Rare Disease Survey – We Need YOU: What’s the cost of living with a rare disease to YOU? If you or a member of your household is living with a rare disease, EveryLife Foundation asks you to take the National Burden of Rare Disease Survey. Deadline to...

May 9, 2020

New research on the use of claims data for gene therapy trials will be presented by HVH Precision Analytics and Diligentia Strategy during the upcoming 2020 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (May 12-15, 2020). This poster presentation wil...

January 8, 2020

In 2019, 44% of novel drugs approved in the U.S were classified with orphan designation.

60% of approved drugs fell into one or more expedited categories: Fast Track, Breakthrough, Priority Review, and/or Accelerated Approval.

  • But how does public conce...

December 2, 2019

If you are attending the J.P. Morgan Healthcare Conference and would like to learn about how Diligentia can support your commercial business objectives, email us to arrange an on-site meeting: joff@diligentiastrategy.com

August 15, 2019

If you are attending the conference and would like to learn about how Diligentia can support your commercial business objectives, email us to arrange an on-site meeting: joff@diligentiastrategy.com

November 16, 2018

If you are attending the conference and would like to learn about how Diligentia can support your commercial business objectives, email us to arrange an on-site meeting: joff@diligentiastrategy.com

April 19, 2018

If you are attending the conference and would like to learn about how Diligentia can support your commercial business objectives, email us to arrange an on-site meeting: joff@diligentiastrategy.com

November 13, 2017

If you are attending the conference and would like to learn about how Diligentia can support your commercial business objectives, email us to arrange an on-site meeting: joff@diligentiastrategy.com

October 22, 2017

Joff Masukawa, Diligentia Strategy, will be the featured speaker at the November 3rd Virginia Bioscience Commercialization Luncheon. He will address commercialization strategies for biopharmaceuticals with a focus on the marketplace for rare diseases, orphan drugs, and...

Please reload

Recent Posts
  • LinkedIn Social Icon
Please reload

© 2019 Diligentia LLC

(202) 744-0755